Adaptive Cardiac Resynchronization Therapy Study (aCRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00980057
Recruitment Status : Unknown
Verified September 2012 by Medtronic Cardiac Rhythm and Heart Failure.
Recruitment status was:  Active, not recruiting
First Posted : September 18, 2009
Last Update Posted : September 11, 2012
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure

Brief Summary:
The purpose of this study is to show that Adaptive CRT is at least as good at optimizing a patient's cardiac resynchronization therapy (CRT) as the current method of using an echocardiogram. Adaptive CRT (aCRT) is an implantable heart failure device feature that attempts to optimize CRT without echocardiographic testing.

Condition or disease Intervention/treatment Phase
Heart Failure Device: Cardiac Resynchronization Therapy-Defibrillator (CRT-D) Other: Adaptive CRT (aCRT) Pacing Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 522 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Adaptive Cardiac Resynchronization Therapy Study
Study Start Date : November 2009
Actual Primary Completion Date : July 2011
Estimated Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Adaptive CRT (aCRT) Pacing
Cardiac resynchronization therapy (CRT) with adaptive pacing
Device: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Market approved Medtronic Vision 3D™ CRT-D implantable device (Consulta® CRT-D, Maximo II® CRT-D, or Concerto II® CRT-D)
Other Names:
  • Consulta® CRT-D
  • Maximo II® CRT-D
  • Concerto II® CRT-D
Other: Adaptive CRT (aCRT) Pacing
Adaptive CRT pacing software adjusts how the device paces the heart based on the patient's current heart status
Other Name: AdaptivCRT
Active Comparator: Standard Biventricular Pacing
Cardiac resynchronization therapy (CRT) with biventricular pacing only (without adaptive pacing)
Device: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Market approved Medtronic Vision 3D™ CRT-D implantable device (Consulta® CRT-D, Maximo II® CRT-D, or Concerto II® CRT-D)
Other Names:
  • Consulta® CRT-D
  • Maximo II® CRT-D
  • Concerto II® CRT-D

Primary Outcome Measures :
  1. Percentage of patients with improved heart failure outcomes Clinical Composite Score [ Time Frame: randomization to six month visit ]
  2. Correlation between aortic velocity time integral (AoVTI) at Adaptive CRT and echo-optimized device settings (AoVTI is an echocardiographic representative of stroke volume and cardiac performance.) [ Time Frame: randomization visit and six month visit ]
  3. Percentage of patients with a safety event (inappropriate AV or VV delay settings related to the aCRT feature) [ Time Frame: 6 months post randomization ]

Secondary Outcome Measures :
  1. Right ventricular pacing percentage [ Time Frame: implant to six months post randomization ]
  2. Change in left ventricular end systolic volume index (LVESVi) [ Time Frame: baseline to six month visit ]
  3. Change in left ventricular ejection fraction (LVEF) [ Time Frame: baseline to six month visit ]
  4. Change in New York Heart Association (NYHA) classification [ Time Frame: baseline to six month visit ]
  5. Change in distance walked during the six minute hall walk [ Time Frame: baseline to six month visit ]
  6. Change in quality of life measured by the Minnesota Living With Heart Failure Questionnaire (MLWHF) [ Time Frame: baseline to six month visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is willing to sign and date the study Informed Consent form
  • Subject is at least 18 years of age (or older, if required by local law)
  • Subject is expected to remain available for at least six months of follow-up visits
  • Subject is indicated for a study device that will be implanted within 30 days after signing the Informed Consent form
  • Subject has an intrinsic QRS duration greater than or equal to 120 milliseconds (documented within 30 days prior to enrollment)
  • Subject has a left ventricular ejection fraction less than or equal to 35 percent (method per physician discretion) (documented within 180 days prior to enrollment)
  • Subject is diagnosed with New York Heart Association (NYHA) class III or IV (within 30 days prior to enrollment) despite optimal medical therapy which is defined as: ACE-inhibitor (Angiotensin-Converting Enzyme) or Angiotensin II Receptor Blocker (ARB), if tolerated, for at least one month prior to implant, AND beta-blocker for at least three months preceding implant, if tolerated, and stable for one month, OR subject has an urgent medical need for an implantable cardioverter defibrillator (ICD) that precludes waiting the one or three months for the medication requirements for ACE inhibitor, ARB or beta-blocker

Exclusion Criteria:

  • Subject has chronic (permanent) atrial arrhythmias for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted
  • Subject has existing CRT system
  • Subject has non-intact or unstable leads
  • Subject has medical conditions that would limit study participation (per physician discretion)
  • Subject is enrolled in one or more concurrent studies that would confound the study results of this study as determined by Medtronic
  • Subject has unstable angina, or experienced an acute myocardial infarction (MI) or received coronary artery revascularization (CABG) or coronary angioplasty (PTCA) (documented within 30 days prior to enrollment)
  • Subject has a mechanical right heart valve or is scheduled to undergo valve repair or valve replacement during the course of the study
  • Subject is post-heart transplant (subjects on the heart transplant list for the first time are not excluded)
  • Subject has a limited life expectancy that would not allow completion of the 6 month visit
  • Subject is pregnant (In the United States, all women of child-bearing potential must undergo a pregnancy test within seven days prior to aCRT download into device)
  • Subject meets the exclusion criteria required by local law

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00980057

  Hide Study Locations
United States, Alabama
Huntsville, Alabama, United States
United States, Alaska
Anchorage, Alaska, United States
United States, Arizona
Phoenix, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Glendale, California, United States
San Bernardino, California, United States
San Diego, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
Denver, Colorado, United States
United States, Florida
Clearwater, Florida, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Pensacola, Florida, United States
United States, Georgia
Augusta, Georgia, United States
United States, Illinois
Barrington, Illinois, United States
United States, Indiana
Fort Wayne, Indiana, United States
United States, Iowa
Davenport, Iowa, United States
Des Moines, Iowa, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Maryland
Takoma Park, Maryland, United States
United States, Massachusetts
Burlington, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Grand Rapids, Michigan, United States
Saginaw, Michigan, United States
United States, Minnesota
St. Cloud, Minnesota, United States
St. Louis Park, Minnesota, United States
St. Paul, Minnesota, United States
United States, Mississippi
Tupelo, Mississippi, United States
United States, Missouri
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
United States, Nebraska
Lincoln, Nebraska, United States
United States, New Jersey
Morristown, New Jersey, United States
United States, New York
Brooklyn, New York, United States
Buffalo, New York, United States
New York, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
United States, Ohio
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, South Carolina
Charlston, South Carolina, United States
Spartanburg, South Carolina, United States
United States, Tennessee
Chattanooga, Tennessee, United States
United States, Texas
Austin, Texas, United States
Dallas, Texas, United States
Tyler, Texas, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Norfolk, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Bellingham, Washington, United States
Spokane, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Adelaide, Australia
Camperdown, Australia
Chermside, Australia
Darlinghurst, Australia
Perth, Australia
Springhill, Australia
Linz, Austria
Genk, Belgium
Leuven, Belgium
Yvoir, Belgium
Calgary, Canada
London, Canada
Montreal, Canada
Newmarket, Canada
Ottawa, Canada
Victoria, Canada
Aalborg, Denmark
København, Denmark
Odense, Denmark
Århus, Denmark
Bochum, Germany
Hamburg, Germany
Ludenscheid, Germany
Reinbek, Germany
Trier, Germany
Athens, Greece
Hong Kong
Hong Kong Island, Hong Kong
Budapest, Hungary
Milano, Italy
Pavia, Italy
Pedara, Italy
Rozzano, Italy
Osaka, Japan
Tokyo, Japan
Tsukuba city, Japan
Nijmegen, Netherlands
Rotterdam, Netherlands
Bergen, Norway
Oslo, Norway
Russian Federation
Tyumen, Russian Federation
Saudi Arabia
Riyadh, Saudi Arabia
Belgrade, Serbia
Nis, Serbia
Sremska Kamenica, Serbia
Albacete, Spain
Madrid, Spain
Majadahonda, Spain
Vitoria-Gasteiz, Spain
Lund, Sweden
Stockholm, Sweden
Lund, Switzerland
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
Study Chair: Adaptive CRT Trial Leader Medtronic

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medtronic Cardiac Rhythm and Heart Failure Identifier: NCT00980057     History of Changes
Other Study ID Numbers: Adaptive CRT
First Posted: September 18, 2009    Key Record Dates
Last Update Posted: September 11, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases